Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up - Archive ouverte HAL Access content directly
Journal Articles Blood Cancer Journal Year : 2020

Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up

(1) , (2) , (3) , (3) , (4) , (4) , (5) , (6) , (6) , (6) , (6) , (7) , (8) , (9) , (9) , (10) , (10) , (10) , (11) , (11) , (12) , (13) , (14) , (15) , (16) , (17) , (18) , (19) , (19) , (20) , (20) , (21) , (2) , (22, 1, 23) , (22, 1, 23) , (2)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
Edouard Cornet
Stéphanie Noël
  • Function : Author
Cécile Tomowiak
  • Function : Author
Jehan Dupuis
  • Function : Author
Agnès Olivrie
  • Function : Author
Mohamed Touati
  • Function : Author
Olivier Hermine
Fabienne Huysman
  • Function : Author
Kamel Ghomari
  • Function : Author
Gandhi Damaj
  • Function : Author
Xavier Troussard
  • Function : Correspondent author
  • PersonId : 855408

Connectez-vous pour contacter l'auteur

Abstract

Abstract In total, 279 patients with hairy-cell leukemia (HCL) were analyzed, with a median follow-up of 10 years. Data were collected up to June 2018. We analyzed responses to treatment, relapses, survival, and the occurrence of second malignancies during follow-up. The median age was 59 years. In total, 208 patients (75%) were treated with purine analogs (PNAs), either cladribine (159) or pentosatin (49), as the first-line therapy. After a median follow-up of 127 months, the median overall survival was 27 years, and the median relapse-free survival (RFS) was 11 years. The cumulative 10-year relapse incidence was 39%. In patients receiving second-line therapy, the median RFS was 7 years. For the second-line therapy, using the same or another PNA was equivalent. We identified 68 second malignancies in 59 patients: 49 solid cancers and 19 hematological malignancies. The 10-year cumulative incidences of cancers, solid tumors, and hematological malignancies were 15%, 11%, and 5.0%, respectively, and the standardized incidence ratios were 2.22, 1.81, and 6.67, respectively. In multivariate analysis, PNA was not a risk factor for second malignancies. HCL patients have a good long-term prognosis. PNAs are the first-line treatment. HCL patients require long-term follow-up because of their relatively increased risk of second malignancies.
Fichier principal
Vignette du fichier
s41408-020-0328-z.pdf (905.37 Ko) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-03495791 , version 1 (20-12-2021)

Identifiers

Cite

Jérôme Paillassa, Edouard Cornet, Stéphanie Noël, Cécile Tomowiak, Stéphane Lepretre, et al.. Analysis of a cohort of 279 patients with hairy-cell leukemia (HCL): 10 years of follow-up. Blood Cancer Journal, 2020, 10 (5), pp.62. ⟨10.1038/s41408-020-0328-z⟩. ⟨inserm-03495791⟩
33 View
16 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More